240 related articles for article (PubMed ID: 34410954)
1. Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Pinto CA; DE Sousa Portilho AJ; Barbosa MC; DE Moraes MEA; DE Lemos JAR; Burbano RMR; Moreira-Nunes CA
In Vivo; 2021; 35(5):2661-2667. PubMed ID: 34410954
[TBL] [Abstract][Full Text] [Related]
2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
3. ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Wang Z; Liu Z; Wu X; Chu S; Wang J; Yuan H; Roth M; Yuan YC; Bhatia R; Chen W
PLoS Genet; 2014 Jun; 10(6):e1004414. PubMed ID: 24967705
[TBL] [Abstract][Full Text] [Related]
4. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
5. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
[TBL] [Abstract][Full Text] [Related]
6. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
8. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
9. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
10. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.
Hatziieremia S; Jordanides NE; Holyoake TL; Mountford JC; Jørgensen HG
Exp Hematol; 2009 Jun; 37(6):692-700. PubMed ID: 19394750
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
13. The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.
Haaß W; Stehle M; Nittka S; Giehl M; Schrotz-King P; Fabarius A; Hofmann WK; Seifarth W
PLoS One; 2012; 7(8):e42863. PubMed ID: 22870341
[TBL] [Abstract][Full Text] [Related]
14. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
18. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
19. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
